 Unum Therapeutics Inc. UMRX, a biopharmaceutical company focused on developing curative cell therapies for solid tumors, today announced financial results for the first quarter ended March 31, 2020, and provided corporate updates. Announced plans to prioritize resources towards advancing its preclinical program, BOXR1030, for the treatment of solid tumor cancers: On March 2nd, Unum announced a corporate restructuring plan to prioritize resources towards advancing its preclinical program, BOXR1030, for the treatment of solid tumor cancers. Unums BOXR1030 expresses a glypican-3 GPC3 targeted CAR and incorporates the novel transgene glutamic-oxaloacetic transaminase 2 GOT2 to improve T cell function in the solid tumor microenvironment by enhancing T cell metabolism. 